Dateline City:
KENILWORTH, N.J.
These and other post-hoc subgroup analyses from TRA-2°P are being presented at the 2015 American College of Cardiology Scientific Sessions
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK),
known as MSD outside the United States and Canada, today announced
results from two post-hoc analyses of the TRA 2°P TIMI 50 (Thrombin
Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic
Events) trial of ZONTIVITY (vorapaxar), one of the largest secondary
prevention studies of an antiplatelet medicine.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558orMichael Close, 267-305-1211orInvestors:Justin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more